Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug421 | Attention Control Text Messaging Wiki | 1.00 |
| drug467 | BAT2020 Wiki | 1.00 |
| drug739 | CBT Text Messaging Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000374 | Aggression NIH | 1.00 |
| D000428 | Alcohol Drinking NIH | 0.35 |
| D013315 | Stress, Psychological NIH | 0.17 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
We will recruit sexual and gender minority couples to complete 56 days of daily surveys in order to evaluate (1) the impact of COVID-19 stress and sexual and gender minority stress on heavy episodic drinking and intimate partner violence (IPV) perpetration, and (2) a brief, mobile-phone delivered text messaging intervention to mitigate the effects of these stressors. This project has high potential to inform how pandemic stress contributes to etiological models of alcohol-related IPV perpetration in sexual and gender minority couples and inform a culturally-sensitive, low burden, and easy to disseminate intervention to mitigate these effects critical during a pandemic when access to care is limited.
Description: Participants will be asked if they experienced relationship conflict since the last report. If so, they will be asked questions about physical and/or verbal perpetration and victimization and time of occurrence.
Measure: Intimate Partner Violence Events (Burst 1) Time: Burst 1, Daily for 14 daysDescription: Participants will be asked if they experienced relationship conflict since the last report. If so, they will be asked questions about physical and/or verbal perpetration and victimization and time of occurrence.
Measure: Intimate Partner Violence Events (Burst 2) Time: Burst 2, Daily for 14 daysDescription: Participants will be asked if they experienced relationship conflict since the last report. If so, they will be asked questions about physical and/or verbal perpetration and victimization and time of occurrence.
Measure: Intimate Partner Violence Events (Burst 3) Time: Burst 3, Daily for 14 daysDescription: Participants will be asked if they experienced relationship conflict since the last report. If so, they will be asked questions about physical and/or verbal perpetration and victimization and time of occurrence.
Measure: Intimate Partner Violence Events (Burst 4) Time: Burst 4, Daily for 14 daysDescription: Participants will be asked if they consumed alcohol since the last daily report. If so, they will be asked questions about the time they drank, amount of alcohol consumed, subjective intoxication, location, with whom they drank, and illicit substance use.
Measure: Drinking Episodes (Burst 1) Time: Burst 1, Daily for 14 daysDescription: Participants will be asked if they consumed alcohol since the last daily report. If so, they will be asked questions about the time they drank, amount of alcohol consumed, subjective intoxication, location, with whom they drank, and illicit substance use.
Measure: Drinking Episodes (Burst 2) Time: Burst 2, Daily for 14 daysDescription: Participants will be asked if they consumed alcohol since the last daily report. If so, they will be asked questions about the time they drank, amount of alcohol consumed, subjective intoxication, location, with whom they drank, and illicit substance use.
Measure: Drinking Episodes (Burst 3) Time: Burst 3, Daily for 14 daysDescription: Participants will be asked if they consumed alcohol since the last daily report. If so, they will be asked questions about the time they drank, amount of alcohol consumed, subjective intoxication, location, with whom they drank, and illicit substance use.
Measure: Drinking Episodes (Burst 4) Time: Burst 4, Daily for 14 daysDescription: Participants will be asked if they experienced discrimination related to their sexual or gender identity.
Measure: Sexual or Gender Minority Stress (Burst 1) Time: Burst 1, Daily for 14 daysDescription: Participants will be asked if they experienced discrimination related to their sexual or gender identity.
Measure: Sexual or Gender Minority Stress (Burst 2) Time: Burst 2, Daily for 14 daysDescription: Participants will be asked if they experienced discrimination related to their sexual or gender identity.
Measure: Sexual or Gender Minority Stress (Burst 3) Time: Burst 3, Daily for 14 daysDescription: Participants will be asked if they experienced discrimination related to their sexual or gender identity.
Measure: Sexual or Gender Minority Stress (Burst 4) Time: Burst 4, Daily for 14 daysDescription: Participants will be asked if they experienced stress related to the COVID-19 pandemic.
Measure: COVID-19 Stress (Burst 1) Time: Burst 1, Daily for 14 daysDescription: Participants will be asked if they experienced stress related to the COVID-19 pandemic.
Measure: COVID-19 Stress (Burst 2) Time: Burst 2, Daily for 14 daysDescription: Participants will be asked if they experienced stress related to the COVID-19 pandemic.
Measure: COVID-19 Stress (Burst 3) Time: Burst 3, Daily for 14 daysDescription: Participants will be asked if they experienced stress related to the COVID-19 pandemic.
Measure: COVID-19 Stress (Burst 4) Time: Burst 4, Daily for 14 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports